文献速递头颈部肿瘤放疗

口咽癌术后黏膜保护性放疗的前瞻性研究

A Prospective Study of Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-10-26

这项前瞻性队列研究纳入61例p16阳性口咽癌术后患者,对高危淋巴结区放疗而避开原发黏膜部位,44例接受质子治疗、17例接受调强放疗。中位随访38个月,2年局部控制率98%、总生存率100%,生活质量多个领域随时间显著改善,吞咽功能稳定。

要点

  • 术后黏膜保护性放疗在原发黏膜部位复发风险低
  • 2年局部控制率98%、无远处转移生存率98%、总生存率100%
  • 生活质量疼痛、吞咽、言语等领域随时间显著改善(均P<.02)

核心结论

  • 对经选择的p16阳性口咽癌术后患者,黏膜保护性放疗耐受良好,原发黏膜部位复发风险低,经皮内镜下胃造瘘置管率低,放疗相关≥3级不良事件少。

研究设计与样本

  • 2016年3月至2019年5月在多站点机构开展经机构审查委员会批准的前瞻性队列研究,纳入p16阳性、美国癌症联合委员会第七版病理T1或T2、N1至N3、M0的口咽癌患者,共61例可评估。

主要发现

  • 61例可评估患者中位随访38个月(范围10-64),44例(72%)接受质子治疗,17例(28%)接受调强放疗。
  • 2年局部控制率98%、局部区域控制率97%、无远处转移生存率98%、总生存率100%。
  • 6例发生治疗相关≥3级事件;2例调强放疗患者因味觉障碍所致明显恶心在治疗期间需经皮内镜下胃造瘘置管。
  • 患者疼痛、吞咽、言语、社交进食、社交接触、张口及止痛药使用等生活质量领域随时间显著改善(均P<.02)。
  • 改良钡餐吞咽障碍剖面总体严重度评分及口腔、咽部障碍评分保持稳定,随时间无显著变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our objective was to report the prospective results of mucosal sparing radiation therapy in human papillomavirus-related oropharyngeal squamous cell carcinoma. METHODS AND MATERIALS: From March 2016 through May 2019, patients were enrolled in this institutional review board-approved prospective cohort study at a multisite institution. Inclusion criteria included p16+ American Joint Committee on Cancer seventh edition pathologic T1 or T2, N1 to N3, and M0 oropharyngeal cancers. Proton therapy (PT) was delivered to at-risk nodal regions, excluding the primary mucosal site. Secondary to insurance denial for PT, intensity modulated radiation therapy (IMRT) was allowed. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module and Patient-Reported Outcomes Measurement Information System surveys (quality of life [QOL]) and modified barium swallowing impairment profiles (MBSImP) were obtained at baseline before radiation therapy, then 3 and 12 months after radiation therapy. Kaplan-Meier estimates were calculated for time-to-event clinical outcomes, and repeated measures mixed models were used to explore changes in QOL over time. A comparison of QOL and swallowing outcomes with standard-of-care treatment was analyzed. RESULTS: There were 61 evaluable patients with a median follow-up of 38 months (range, 10-64); 44 (72%) were treated with PT and 17 (28%) were treated with IMRT. The 2-year local control, locoregional control, distant metastasis-free survival, and overall survival were 98%, 97%, 98%, and 100%, respectively. There were 6 grade ≥3 events related to treatment. Two IMRT patients required percutaneous endoscopic gastrostomy tube placement during treatment secondary to significant nausea due to dysgeusia. Patients noted significant QOL improvement over time in the pain, swallowing, speech, social eating, social contact, mouth opening, and use of pain medication domains (all P < .02). The MBSImP overall severity score as well as oral and pharyngeal impairment scores showed stability with no significant change over time. For the 44 patients treated with PT, the mean D95 to the primary target was 10.7 Gy (standard deviation = 12.5 Gy). CONCLUSIONS: Mucosal sparing radiation is well tolerated in select resected human papillomavirus-related oropharyngeal squamous cell carcinoma with a low risk of recurrence at the mucosal primary site, a low rate of percutaneous endoscopic gastrostomy tube placement, and few radiation-related grade ≥3 adverse events.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Anderson JD, DeWees TA, Ma DJ, et al. A Prospective Study of Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer Patients. Int J Radiat Oncol Biol Phys. 2022. PMID: 36309077. doi:10.1016/j.ijrobp.2022.06.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。